We are live on ! Find out more
Nisa Investment Advisors

Nisa Investment Advisors Portfolio holdings

AUM $27B
1-Year Est. Return 24.49%
This Fund
S&P 500
This Quarter Est. Return
+5.57%
1 Year Est. Return
+24.49%
3 Year Est. Return
+88.53%
5 Year Est. Return
+114.58%
10 Year Est. Return
+419.26%
AUM
$7.28B
AUM Growth
+$144M
Cap. Flow
-$156M
Cap. Flow %
-2.15%
Top 10 Hldgs %
15.71%
Holding
1,346
New
48
Increased
203
Reduced
562
Closed
64

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$13.5M
2
PFE icon
Pfizer
PFE
+$7.77M
3
MRK icon
Merck
MRK
+$7.43M
4
GILD icon
Gilead Sciences
GILD
+$6.93M
5
VZ icon
Verizon
VZ
+$6.27M

Sector Composition

Rank Sector Weight
1 Financials 14.62%
2 Technology 14.54%
3 Healthcare 13.65%
4 Industrials 10.98%
5 Consumer Staples 8.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VWO icon
26
Vanguard FTSE Emerging Markets ETF
VWO
$124B
$49.3M 0.68%
1,230,985
AMGN icon
27
Amgen
AMGN
$221B
$48M 0.66%
301,179
-33,533
-10% -$5.23M
VZ icon
28
Verizon
VZ
$189B
$47.6M 0.65%
1,017,757
-128,150
-11% -$6.27M
PEP icon
29
PepsiCo
PEP
$189B
$47.5M 0.65%
501,830
-9,135
-2% -$876K
PM icon
30
Philip Morris
PM
$290B
$47.4M 0.65%
581,954
-11,901
-2% -$1.02M
CVS icon
31
CVS Health
CVS
$125B
$46.7M 0.64%
484,565
-10,035
-2% -$884K
UNP icon
32
Union Pacific
UNP
$175B
$42M 0.58%
352,746
-8,360
-2% -$960K
QCOM icon
33
Qualcomm
QCOM
$167B
$41.9M 0.58%
563,937
-13,740
-2% -$1.01M
UNH icon
34
UnitedHealth
UNH
$372B
$41.9M 0.58%
414,218
-43,482
-10% -$4.12M
GILD icon
35
Gilead Sciences
GILD
$162B
$41.6M 0.57%
441,121
-67,016
-13% -$6.93M
V icon
36
Visa
V
$687B
$41.4M 0.57%
631,344
-10,504
-2% -$632K
META icon
37
Meta Platforms (Facebook)
META
$1.5T
$40.6M 0.56%
520,657
+6,268
+1% +$479K
COP icon
38
ConocoPhillips
COP
$140B
$39.2M 0.54%
567,728
-9,876
-2% -$689K
AXP icon
39
American Express
AXP
$235B
$38.6M 0.53%
415,320
-11,949
-3% -$1.07M
MMM icon
40
3M
MMM
$94.2B
$38.2M 0.52%
277,861
-7,594
-3% -$975K
MO icon
41
Altria Group
MO
$113B
$36.5M 0.5%
741,298
-8,785
-1% -$428K
BMY icon
42
Bristol-Myers Squibb
BMY
$130B
$35.7M 0.49%
604,188
-66,135
-10% -$3.73M
VEU icon
43
Vanguard FTSE All-World ex-US ETF
VEU
$68.2B
$35.4M 0.49%
755,000
RTX icon
44
RTX Corp
RTX
$296B
$34.7M 0.48%
480,131
-9,216
-2% -$628K
SLB icon
45
SLB Ltd
SLB
$74.7B
$34.6M 0.48%
405,369
-9,147
-2% -$842K
TFCFA
46
DELISTED
Twenty-First Century Fox, Inc. Class A
TFCFA
$32.8M 0.45%
855,052
-18,023
-2% -$638K
ABBV icon
47
AbbVie
ABBV
$437B
$32.6M 0.45%
498,872
-69,339
-12% -$4.37M
AMZN icon
48
Amazon
AMZN
$2.98T
$32.3M 0.44%
2,079,800
-32,000
-2% -$499K
HPQ icon
49
HP
HPQ
$25.9B
$32.2M 0.44%
1,766,929
-46,689
-3% -$782K
USB icon
50
US Bancorp
USB
$100B
$32M 0.44%
712,669
-2,200
-0.3% -$94.7K

Similar funds

Nisa Investment Advisors's Q4 2014 Portfolio in Review

As of Q4 2014, Nisa Investment Advisors held 1,346 positions worth $7.28B, up 2% from $7.13B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Nisa Investment Advisors's Q4 2014 filing shows 48 new, 203 increased, 562 reduced and 64 closed positions. Its largest new stake was CDK Global, Inc.: 61,543 shares worth $2.51M. The largest sale was Johnson & Johnson, an estimated $13.5M.

By sector, the portfolio is most concentrated in Financials at 15% of assets, up from 14% a quarter earlier, followed by Technology and Healthcare.

  • Nisa Investment Advisors's largest Q4 2014 buy was CDK Global, Inc.: 61,543 shares worth $2.51M.
  • Nisa Investment Advisors added most to Kinder Morgan in Q4 2014, an estimated $5.08M increase.
  • Nisa Investment Advisors's biggest Q4 2014 reduction was Johnson & Johnson, cutting an estimated $13.5M.
  • Nisa Investment Advisors fully exited TW TELECOM INC CL A COM in Q4 2014, selling an estimated $3.92M.
  • Nisa Investment Advisors's ten largest holdings make up 16% of its $7.28B portfolio in Q4 2014.
  • Nisa Investment Advisors opened 48 new positions and closed 64 in Q4 2014.
  • Nisa Investment Advisors's portfolio value rose 2% quarter-over-quarter to $7.28B.

Based on Nisa Investment Advisors's 13F filing for Q4 2014, filed 6 Feb 2015.